{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-003470","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2021-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.176778+00:00","generated_at":"2026-06-28T11:41:23.365322+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ORIC Pharmaceuticals reports Q3 2021 cash of $296.5M, ORIC-101 early clinical data, and upcoming pipeline milestones","bullets":["Cash, cash equivalents and investments of $296.5 million, expected to fund operations into 2024.","Initial Phase 1b data for ORIC-101 combo with enzalutamide showed safe profile and antitumor activity in 6 of 8 key patients.","R&D expenses $12.9M (Q3 2021) vs $8.8M (Q3 2020); G&A expenses $5.6M vs $3.8M.","Anticipated Q4 2021 milestones: initiate Phase 1 trial for ORIC-533 in multiple myeloma and file IND for ORIC-944."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-003470","json":"https://secwatch.observer/filing/0000950170-21-003470.json","markdown":"https://secwatch.observer/filing/0000950170-21-003470.md","text":"https://secwatch.observer/filing/0000950170-21-003470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017021003470/0000950170-21-003470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017021003470/oric-20211108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T11:41:23.365322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}